Spanish drugmaker Almirall, moving on from its former focus on respiratory therapies, is beefing up its dermatology pipeline with a buyout of Switzerland's Poli Group. Under the deal, Almirall is acquiring all of Poli's shares for €365 million ($386 million), bringing in three clinical dermatology candidates and an R&D infrastructure the company said will help it generate more shots on goal in the field. Last year, Almirall signed away its respiratory business to AstraZeneca ($AZN) in a $2.1 billion deal, and the company has since been building up its capacity in treatments for skin disorders. More